Usually around this time of year, I do a video that's basically a review of all that's happened in the prior year. But this year, I decided to do something a bit different. Instead of reviewing 2015, I'm going to talk about what I'd like to see happen in 2016. So, this is my wish list. It's not a set of predictions per se, but it covers what I'd like to see happen in diabetes care in the next year, and what I hope you all can help me accomplish.
SGLT-2 Inhibitors: Validation of Benefits and Wider Adoption
First off, I will say that one remarkable study, the EMPA-REG trial, changed how I look at the treatment of type 2 diabetes. As a reminder, EMPA-REG was the cardiovascular outcomes trial that looked at empagliflozin compared with placebo and showed a big difference, both in terms of cardiovascular mortality, overall mortality, and hospitalization for congestive heart failure. This was truly the first study that showed a diabetes drug can reduce macrovascular complications.
What I'd like is to see EMPA-REG more translated into our practice in the year going forward, and there are a variety of ways in which I'd like to see this happen.
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus Clinical Practice Guidelines (SID/AMD, 2022)
Pediatric Type 2 Diabetes Mellitus
COMMENTARY
What I Want for Christmas (Next Year)
Diabetes Expert Highlights Wishes for the Coming Year
Anne L. Peters, MD
DisclosuresDecember 23, 2015
Usually around this time of year, I do a video that's basically a review of all that's happened in the prior year. But this year, I decided to do something a bit different. Instead of reviewing 2015, I'm going to talk about what I'd like to see happen in 2016. So, this is my wish list. It's not a set of predictions per se, but it covers what I'd like to see happen in diabetes care in the next year, and what I hope you all can help me accomplish.
SGLT-2 Inhibitors: Validation of Benefits and Wider Adoption
First off, I will say that one remarkable study, the EMPA-REG trial, changed how I look at the treatment of type 2 diabetes. As a reminder, EMPA-REG was the cardiovascular outcomes trial that looked at empagliflozin compared with placebo and showed a big difference, both in terms of cardiovascular mortality, overall mortality, and hospitalization for congestive heart failure. This was truly the first study that showed a diabetes drug can reduce macrovascular complications.
What I'd like is to see EMPA-REG more translated into our practice in the year going forward, and there are a variety of ways in which I'd like to see this happen.
Medscape Diabetes © 2015 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Anne L. Peters. What I Want for Christmas (Next Year) - Medscape - Dec 23, 2015.
Tables
Authors and Disclosures
Authors and Disclosures
Author(s)
Anne L. Peters, MD
Professor of Clinical Medicine; Director, Clinical Diabetes Programs, Keck School of Medicine, University of Southern California, Los Angeles, California
Disclosure: Anne L. Peters, MD, has disclosed the following financial relationships:
Served as director, officer, partner, employee, advisor, consultant, or trustee for: (current consultant): Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Novo Nordisk
Served as a speaker or member of a speaker's bureau for: (current speakers bureau member): Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Novo Nordisk; Takeda Pharmaceuticals North America, Inc.
Served as a consultant or ad hoc speaker/consultant for: AstraZeneca Pharmaceuticals LP; Abbott Laboratories; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Dexcom; Medtronic MiniMed, Inc.; Merck & Co., Inc.; Roche; sanofi-aventis